Skip to main content
SpringerLink
Log in

Krankheiten der Leber und Gallenwege

  • Chapter
Die ärztliche Begutachtung

  • 5330 Accesses

Zusammenfassung

Die Mehrzahl der Gallenwegsverletzungen ereignet sich bei Operationen. Als Folge können sich Gallenfisteln in die freie Bauchhöhle, den Magen-Darm-Trakt oder das Bronchialsystem oder Strikturen der Gallenwege entwickeln. Bei daraus entstehenden chronischen Cholangitiden und Cholestasen ist die Entwicklung einer biliären Leberzirrhose möglich. Verletzungen der Leber können akut zu lebensbedrohlichen Blutungen und Schockzuständen führen. Die Bestimmung von GdB/GdS/MdE orientiert sich an sekundären Funktionsstörungen. Wegen der guten Regenerationsfähigkeit des Leberparenchyms sind anhaltende Störungen der Organfunktion nach Lebertrauma die Ausnahme.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

Zu 14.2

  1. Cornberg M, Protzer U, Dollinger MM, et al. (2007) Prophylaxe, Diagnostik und Therapie der Hepatitis B-Virusinfektion. Upgrade der Leitlinie, AWMF-Register-Nr. 021/011. Z Gastroenterol 45:1–50

    Google Scholar 

  2. Dienstag J (2008) Hepatitis B virus infection. N Engl J Med 359:1486–1500

    Article  PubMed  CAS  Google Scholar 

  3. Heidrich B, Deterding K, Tillmann HL, et al. (2009) Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 16: 883–894

    Article  PubMed  CAS  Google Scholar 

  4. Kwo PY, Lawitzt EJ, McCane J, et al. (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, published online August 9, 2010

    Google Scholar 

  5. Lok ASF, Mcmahon BJ (2009) Chronic Hepatitis B: Update 2009. Hepatology 50:661–662

    Article  PubMed  Google Scholar 

  6. Maheshwari A, Ray S, Thuluvath PJ (2008) Acute Hepatitis C. Lancet 372: 321–332

    Article  PubMed  Google Scholar 

  7. Marcellin P, Bonino F, Lau GGK, et al. (2009) Sustained response of Hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136:2169–2179

    Article  PubMed  CAS  Google Scholar 

  8. McHutchison JG, Lawitz EJ, Shiffman ML, et al. (2009) Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med 361:580–593

    Article  PubMed  CAS  Google Scholar 

  9. McHutchison JG, Everson GT, Gordon SC, et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827–1838

    Article  PubMed  CAS  Google Scholar 

  10. Reiser M (2009) Viral Hepatitis B und C. Med Klin (Munich) 104:356–362

    Article  CAS  Google Scholar 

  11. Reiser M, Timm J (2009) Serine protease inhibitors as anti-Hepatitis C virus agents. Expert review of anti-infective therapy 7:537–547

    Article  PubMed  CAS  Google Scholar 

  12. Rosen HR (2011) Chronic hepatits C infection. N Engl J Med 364:2429–2438

    Article  PubMed  CAS  Google Scholar 

  13. Sarrazin C, Berg T, Ross RS, et al. (2010) Prophylaxis, diagnosis and therapy of Hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 48:289–351

    Article  PubMed  CAS  Google Scholar 

  14. Swain MG, Lai MY, Shiffmann ML, et al. (2010) A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin. Gastroenterology 139:1593–1601

    Article  PubMed  CAS  Google Scholar 

  15. Wong VW, Wong GLH, Yan KKL, et al. (2010) Durability of peginterferon alfa-2b treatment at 5 years in patients with Hepatitis B e antigen-positive chronic Hepatitis B. Hepatology 51:1945–1953

    Article  PubMed  CAS  Google Scholar 

Zu 14.3

  1. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH (2001) Drug-induced liver injury: mechanisms and test systems. Hepatology 33:1009–1013

    Article  PubMed  CAS  Google Scholar 

  2. Dancygier H (2002) Klinische Hepatologie. Springer, Heidelberg

    Google Scholar 

  3. Gross, Schölmerich J, Gerok W (2000) Fremdstoff-induzierte Leberkrankheiten. In: Gerok W, Huber C, Meinertz T, Zeidler H (Hrsg) Die Innere Medizin. Schattauer, Stuttgart

    Google Scholar 

  4. Gerok W, Blum HE (Hrsg) (1995) Hepatologie, 2. Aufl. Urban und Schwarzenberg, München

    Google Scholar 

  5. Güngerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–650

    Article  Google Scholar 

  6. Huang YS, Chem HD, Su WJ, et al. (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for attenuating drug-induced hepatitis. Hepatology 35:883–889

    Article  PubMed  CAS  Google Scholar 

  7. Hunt CM, Waterkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275–283

    Article  PubMed  CAS  Google Scholar 

  8. Jonsson JR, Edwards-Smith CJ, Catania SC, et al. (2000) Expression of cytokines and factors modulating apoptosis by human sinusoidal lymphocytes. J Hepatol 32:392–398

    Article  PubMed  CAS  Google Scholar 

  9. Lee WM (2003) Drug-Induced Hepatotoxicity. N Engl J Med 349:474–485

    Article  PubMed  CAS  Google Scholar 

  10. Robin MA, Le Roy M, Deseatorie V, Pessayre D (1997) Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 26 (Suppl 1):23–30

    Article  PubMed  CAS  Google Scholar 

  11. Sgro C, Clinard F, Ouazir K, et al (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451–455

    Article  PubMed  Google Scholar 

  12. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529–537

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Behandlungszentrum Paracelsus-Klinik Marl, Klinik für Innere Medizin, Klinikum Vest GmbH, Lipper Weg 11, 45770, Marl, Deutschland

    Markus Reiser Priv.-Doz. Dr. med.

  2. Knappschaftskrankenhaus, Medizinische Universitätsklinik, In der Schornau 23 – 25, 44892, Bochum, Deutschland

    Stefan Heringlake Priv.-Doz. Dr. med.

  3. Medizinische Klinik I, BG-Universitätsklinikum Bergmannsheil, Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Deutschland

    Christian Mölleken Dr. med.

  4. Medizinische Universitätsklinik, Knappschaftskrankenhaus u. Bergmannsheil, In der Schornau 23 – 25, 44892, Bochum, Deutschland

    Wolff Schmiegel Prof. Dr. med.

Authors
  1. Markus Reiser Priv.-Doz. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Heringlake Priv.-Doz. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Mölleken Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolff Schmiegel Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universität Frankfurt am Main, Pulheim, Deutschland

    Jürgen Fritze Prof. Dr.

  2. Deutsche Gesetzliche Unfallversicherung (DGUV), Berlin, Deutschland

    Friedrich Mehrhoff Dr. jur.

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Reiser, M., Heringlake, S., Mölleken, C., Schmiegel, W. (2012). Krankheiten der Leber und Gallenwege. In: Fritze, J., Mehrhoff, F. (eds) Die ärztliche Begutachtung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21081-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21081-5_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21080-8

  • Online ISBN: 978-3-642-21081-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation